FDA Removes Boxed Warning From Menopausal Hormone Therapy

Background Information

FDA removes boxed warning from menopausal hormone therapy, changing safety perceptions.

The removal of the boxed warning on menopausal hormone therapy highlights the evolution in understanding its safety profile, impacting prescribing practices and patient counseling. The FDA decision reflects two decades of evidence showing a revised risk-benefit appraisal of menopausal hormone therapy. Nurses and healthcare providers must update counseling and prescribing practices in light of the removal of the warning, incorporating new evidence into patient discussions. The boxed warning removal signifies updated safety views on menopausal hormone therapy.